Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-09-20

FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for a generic escitalopram oxalate product from Rising Pharma Holdings, expanding access to this SSRI used to treat …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Escitalopram Oxalate (escitalopram oxalate)

Snippet

SUPPL AP for ESCITALOPRAM OXALATE (ESCITALOPRAM OXALATE)